BioAge Labs

IoTeX is a blockchain platform designed to address the challenges and opportunities presented by the Internet of Things (IoT). This comprehensive overview highlights its key features and functionalities: ### Architecture and Scalability IoTeX employs a unique "blockchain-within-a-blockchain" architecture, featuring a public root chain and independent subchains. This hierarchical structure enhances scalability by separating duties into tailored sidechains, allowing efficient handling of diverse IoT devices without overwhelming the root chain. ### Consensus Mechanism The platform uses Roll-DPoS, a randomized version of the Delegated Proof-of-Stake (DPoS) consensus mechanism. This approach randomly selects delegates to create new blocks, enhancing efficiency and reducing centralization. Roll-DPoS enables fast transaction processing, handling over 2000 transactions per second with block finalization within 5 seconds. ### Privacy and Security Privacy is a critical aspect of IoTeX, incorporating features such as stealth addresses, ring signatures, and BulletProofs for privacy-preserving transactions. The platform also utilizes a decentralized identity (DID) framework, providing permanent, globally unique identifiers without central registration, thus enhancing security and effectiveness of smart device interactions. ### W3bstream and Off-Chain Computing IoTeX's W3bstream protocol enables decentralized applications (dApps) to perform verifiable processing using zero-knowledge proofs, connecting off-chain data sources with blockchain applications. This middleware solution facilitates the computation and verification of real-world data, offering modularity and customizability for builders. ### MachineFi and DePIN IoTeX has developed MachineFi, intersecting machine and DeFi to capitalize on machine-generated data, events, and tasks. This allows users to monetize personal information and smart device data through the IoTeX blockchain. The platform has also evolved into a modular DePIN (Decentralized Physical Infrastructure Network) infrastructure with IoTeX 2.0, including composable modules, a Modular Security Pool, and open-source resources. ### Token and Ecosystem The native token of the IoTeX ecosystem is IOTX, used for network administration, staking, transaction fees, and registering smart devices. IOTX enables participation in protocol governance and access to various resources and dApps on the platform. ### Use Cases IoTeX supports a diverse range of IoT applications, including the sharing economy, smart homes, supply chain management, and device identity management. It provides a secure and decentralized alternative to conventional private cloud infrastructures across various sectors. In summary, IoTeX offers a robust blockchain solution for the IoT ecosystem, providing scalability, privacy, and a modular infrastructure for DePIN projects, making it a versatile platform for the complex IoT landscape.

Masdar, also known as the Abu Dhabi Future Energy Company, is a prominent Emirati state-owned renewable energy company founded in 2006. This comprehensive overview highlights Masdar's key aspects: ### Ownership and Global Presence - Founded by Sultan Al Jaber in 2006 - Jointly owned by Abu Dhabi National Energy Company PJSC (TAQA), Mubadala Investment Company, and Abu Dhabi National Oil Company (ADNOC) - Active in over 40 countries - Invested or committed to invest in projects valued at over $30 billion ### Capacity and Growth - Operational, under construction, and advanced pipeline capacity grew from 20 GW to 51 GW by the end of 2024 - Ambitious target to achieve 100 GW of renewable energy capacity by 2030 - In 2024, deployed nearly $8 billion in equity investments and secured over $4.5 billion in project financing across nine countries ### Technologies and Initiatives - Leader in clean energy technologies: solar, wind, geothermal, battery storage, and green hydrogen - Aims to produce 1 million tonnes of green hydrogen by 2030 - Hosts the International Renewable Energy Agency (IRENA) headquarters at Masdar City - Launched initiatives such as Youth 4 Sustainability (Y4S) and Women in Sustainability, Environment and Renewable Energy (WiSER) ### Masdar City - Flagship project designed as a model for sustainable urban living - Incorporates renewable energy, green building practices, and advanced technology - Masdar City Free Zone hosts over 1,000 organizations, serving as a hub for innovation and sustainability ### Financial and Operational Highlights - Issued a second green bond, raising $1 billion with a 4.6x oversubscription - Credit rating upgraded to AA- by Fitch - Inaugurated the 500MW Zarafshan Wind Farm in Uzbekistan, the largest wind farm in Central Asia - Signed a Power Purchase Agreement for the 2GW Sadawi project in Saudi Arabia Masdar plays a pivotal role in the global transition to renewable energy, driving innovation and supporting sustainable development worldwide.

Syntiant Corp., founded in 2017 and based in Irvine, California, is a technology company specializing in end-to-end deep learning solutions for edge AI applications. The company's focus is on developing ultra-low-power, high-performance deep neural network processors that enable machine learning directly on devices, reducing reliance on cloud computing. Key Products and Technologies: - Digital neural decision processors mimicking the human brain for efficient workload processing - Use-case specific machine learning models for edge processing in sensor, voice, and video applications - Low-power, high-performance solutions suitable for compute-constrained environments Partnerships and Funding: - Backed by prominent investors including Intel Capital, Microsoft's M12, Applied Ventures, Robert Bosch Venture Capital, Amazon Alexa Fund, and Atlantic Bridge Capital - Total funding of $122.93 million, with the latest being Series C - III Applications and Use Cases: - Utilized in various sectors including consumer electronics, industrial automation, and automotive - Notable application in Ring Alarm Glass Break Sensor for efficient, private edge detection Growth and Recognition: - Over 100 employees across the United States, Asia, and Europe - Recognized as one of the "Best Places to Work in Orange County" for five consecutive years - More than 50 million devices deployed globally using Syntiant's technology Vision and Philosophy: Syntiant aims to create seamless human-technology interactions using natural interfaces like voice or gestures, processing data at the edge to enhance privacy and user experience while reducing data congestion between devices and cloud servers.

Umoja Biopharma is a pioneering biotechnology company focused on developing innovative immunotherapies, particularly in the field of cell and gene therapies. The company's mission is to unlock the potential of CAR T cell therapies, making them more accessible, scalable, and effective for patients with solid tumor and blood cancers. Umoja's integrated scientific platforms include: 1. VivoVec: A proprietary, third-generation lentiviral vector technology for in vivo gene delivery, enabling the body to produce its own cancer-fighting CAR T cells. 2. RACR (Rapamycin-Activated Cytokine Receptor): A system using rapamycin to support the survival and expansion of CAR T cells generated in vivo, eliminating the need for lymphodepletion via chemotherapy. 3. iCIL (RACR-induced cytotoxic lymphocytes): A platform generating synthetic cancer-fighting cells from induced pluripotent stem cells (iPSCs) at a large scale. 4. TumorTag: A small molecule that 'tags' cancer and its stromal cells, allowing precise targeting by CAR T cells. Umoja's manufacturing capabilities are centered around The CLIMB (Colorado Laboratory & Innovative Manufacturing Building), a state-of-the-art facility in Louisville, Colorado. This facility supports lentiviral vector development and manufacturing through Phase 2 clinical studies. The company is led by a team of experienced professionals, including co-founders Andrew Scharenberg, MD (CEO) and Ryan Crisman, PhD (CTO). Umoja's approach aims to overcome limitations of current ex vivo cellular immunotherapies by developing 'off-the-shelf' cell therapies that are scalable, cost-effective, and widely accessible.